IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, today announces that it is scheduled to attend and present at the 10th Annual CNS Summit held from 31st October to 3rd November 2019 in Boca Raton, Florida, USA.
10th Annual CNS Summit
31st October - 3rd November 2019, Boca Raton Resort, Florida, USA
Robin Wolz, Senior Vice President of Science & Innovation at IXICO will present a poster entitled "Automated sleep-wake prediction from wearable sensors using neural networks - from data collection to algorithm development, cross-validation and clinical trial deployment" during the evening receptions on Friday 1st and Saturday 2nd November 2019.
This study shows how AI technology improved the analysis of sleep/wake accelerometry from wearables compared to traditional, count-based measurements in a robust and reproducible way. Thus, the exploratory use of this validated algorithm in clinical trials is feasible and provides the collection of evidence needed to support further development of real-world evidence in clinical trial designs.
The rise in people using connected wearable devices has opened the door for the medical field to harness real-time patient health data to support clinical development of many diseases including Alzheimer's and Parkinson's disease.
Founded by R&D leaders, the CNS Summit is a platform of industry leaders working collaboratively to shape the future of the life scienceswith a focus on innovation and technology. The agenda features top leaders from the regulators, pharmaceutical and biotech companies, technology and services companies driving change in the healthcare sector.
Robin Wolz1,2, Luis Peraza1, Richard Joules1, Yves Dauvilliers3
Affiliations: 1- IXICO, London, UK, 2- Imperial College London, London, UK, 3- Department Neurology, Centre Hospitalier Universitaire, Montpellier, France
IXICO's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and rare disease.
Our goal is to be a leading proponent in the use of AI in clinical development, to improve biopharma R&D productivity through the adoption of breakthrough data analytics in precision healthcare. Through the deployment of novel AI algorithms, we analyse and interpret brain scans and digital biosensor data to enable better trial design, patient selection and ultimately clinical outcomes across all phases of clinical evaluation. Our data analytics services are deployed on some of the most important clinical trials in neuroscience and rare disease, providing valuable insights to disease progression and patient safety, enabling our clients to make better informed decisions earlier in the clinical development pathway.
CNS Summit is a platform for change and a community passionate about shaping the future, with a focus on collaboration, innovation, and technology. Its mission is to have a positive impact on the success of clinical development programs. CNS Summit believes this mission is its ethical duty to the patients they serve by developing new treatments.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
IXICO PLC's (LON:IXI) Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM .
For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000...